Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL5143394 | 0.93 | SLC6A4 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL5142785 | 0.89 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL5142911 | 0.89 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL5145138 | 0.86 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL5431028 | 0.84 | SLC6A4 (0.74) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL3856872 | 0.84 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL137619 | 0.84 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL3947169 | 0.84 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL14028076 | 0.84 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Sertraline SCHEMBL3885286 | 0.84 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626950-A4 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1626950-A1 | SERTRALINE COMPOSITIONS | Transform Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2005000786-A1 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| US-7094930-B2 | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20040198818-A1 | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| WO-2004065348-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF SERTRALINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198818-A1 | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof | SLC6A4, SUCNR1, SLC6A11 | SLC6A4 1/4885SLC6A2 8/4885SLC6A3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.